Calcitonin Gene-Related Peptide Receptor Antagonist Market to Surpass $3.48 Billion by 2029 | Key Trends & Insights

Get 30% off global market reports with code ONLINE30 and keep ahead of tariffs, macro trends, and worldwide economic developments.

How Will the Calcitonin Gene-Related Peptide Receptor Antagonist Market Grow by 2025 in Terms of Size and Growth?
The market size for calcitonin gene-related peptide receptor antagonists has been expanding swiftly in recent times. The projection is that it will increase from $2.06 billion in 2024 to $2.30 billion in 2025, representing a compound annual growth rate (CAGR) of 11.2%. The previously observed expansion can be credited to the broadening of clinical tests showing effectiveness, escalating global spending on healthcare, growing identification of migraine disorders, an increasing uptake of preventive treatments for migraines, and a substantial pipeline of CGRP antagonist molecules.

What Are the Estimated Growth Rates for the Calcitonin Gene-Related Peptide Receptor Antagonist Industry Through 2029?
The market size of the calcitonin gene-related peptide receptor antagonist is projected to witness a significant increase in the upcoming years. The market is forecasted to expand to $3.48 billion by 2029, with a compound annual growth rate (CAGR) of 11.0%. The market expansion during the forecast period can be attributed to factors such as positive regulatory approvals, a surge in research funding, a growing preference for newly developed migraine prevention treatments, a rising geriatric population, and an increasing number of elderly individuals. Key trends expected during this forecast period comprise development of oral small molecules, deployment of wearable for facilitating dosing, development of long-lasting injectable formulations, utilization of nanoparticle drug carriers, and exploration of gene therapy.

Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/calcitonin-gene-related-peptide-receptor-antagonist-global-market-report

What Are the Strategic Drivers Boosting Calcitonin Gene-Related Peptide Receptor Antagonist Market Performance?
The escalating occurrence of migraines is projected to drive the calcitonin gene-related peptide receptor antagonist market's expansion. Migraine, an intense headache that can trigger pulsating pain typically on one side of the head, is seeing an increasing occurrence due to heightening stress from fast-paced urban lifestyles, inconsistent sleep patterns, and increased exposure to noise, pollution, and bright lights as urban migration rises. The calcitonin gene-related peptide receptor antagonist aids in relieving migraines by impeding CGRP, a protein that broadens blood vessels and sends pain signals during an attack, hence diminishing the headache pain and other symptoms. For example, a report issued by the National Library of Medicine, a US-based national library, in April 2024 indicated that approximately 61,204 individuals in the US were identified with migraines by a medical professional in 2022, marking a 5.5% increase from 2021. Hence, the escalating occurrence of migraines is stimulating the growth of the calcitonin gene-related peptide receptor antagonist market.

Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25715&type=smp

What Are the Segments in the Calcitonin Gene-Related Peptide Receptor Antagonist Market?
The calcitonin gene-related peptide receptor antagonist market covered in this report is segmented -

1) By Type: Small Molecule Antagonists, Monoclonal Antibodies, Peptide-Based Antagonists
2) By Drug Type: Zavegepant, Ubrogepant, Olcegepant, Telcegepant, Rimegepant, Other Drug Types
3) By Application: Migraine Treatment, Pain Management, Cardiovascular Conditions, Bone Disorders
4) By End-Users: Hospitals, Clinics, Homecare Settings, Pharmaceutical Companies

Subsegments:
1) By Small Molecule Antagonists: Oral Small Molecule Antagonists, Intranasal Small Molecule Antagonists, Injectable Small Molecule Antagonists
2) By Monoclonal Antibodies: Erenumab, Fremanezumab, Galcanezumab, Eptinezumab
3) By Peptide-Based Antagonists: CGRP Fragment-Based Antagonists, Peptidomimetic CGRP Antagonists

What Are the Key Adoption Trends in the Calcitonin Gene-Related Peptide Receptor Antagonist Market?
Leading players in the calcitonin gene-related peptide receptor antagonist market are striving to gain approvals for inventive products like oral CGRP receptor antagonists. The aim is to improve the effectiveness of migraine treatment, widen the scope of therapeutic indications, and provide more user-friendly modes of administration. Oral CGRP receptor antagonists are small-molecule drugs that impede CGRP, a protein associated with migraine episodes, thus assisting in migraine prevention. For example, in April 2023, AbbVie Inc., an American biotech enterprise, earned the approval from the U.S. Food and Drug Administration (FDA) to use QULIPTA (atogepant) for adult chronic migraine treatment. QULIPTA (atogepant) is an oral, once-daily calcitonin gene-related peptide (CGRP) receptor adversary designed for the preventive care of migraines in adults. It has been greenlighted for both episodic and chronic migraine in the US. QULIPTA operates by obstructing the activities of CGRP, a protein that intensifies during migraine episodes and contributes to pain transmission and inflammation in the brain. QULIPTA is offered in 10 mg, 30 mg, and 60 mg tablet forms, with the 60 mg dosage specifically tested for chronic migraine prevention.

Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25715&type=smp

Which Companies Lead the Competitive Landscape of the Calcitonin Gene-Related Peptide Receptor Antagonist Industry?
Major companies operating in the calcitonin gene-related peptide receptor antagonist market are Pfizer Inc., Merck & Co. Inc. , AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Sosei Group Corporation, Teva Pharmaceutical Industries Ltd., UCB S.A., Alder BioPharmaceuticals, Inc. , H. Lundbeck A/S, Otsuka Pharmaceutical Co. Ltd., Biosynth Carbosynth , Seurat Therapeutics Inc., Satsuma Pharmaceuticals Inc., Allergan plc , Brise Pharmaceutical (Shanghai) Co Ltd., Nuvie Biopharma Inc.

Where Are the Key Calcitonin Gene-Related Peptide Receptor Antagonist Market Opportunities by Region?
North America was the largest region in the calcitonin gene-related peptide receptor antagonist market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calcitonin gene-related peptide receptor antagonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.